Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Identifieur interne : 002677 ( Ncbi/Curation ); précédent : 002676; suivant : 002678Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Auteurs : Jahan S. Khalili [États-Unis] ; Hai Zhu [États-Unis] ; Nga Sze Amanda Mak [États-Unis] ; Yongqi Yan [États-Unis] ; Yi Zhu [États-Unis]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.
DOI: 10.1002/jmv.25798
PubMed: 32227493
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000112
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000112
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000127
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002677
Links to Exploration step
pubmed:32227493Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.</title><author><name sortKey="Khalili, Jahan S" sort="Khalili, Jahan S" uniqKey="Khalili J" first="Jahan S" last="Khalili">Jahan S. Khalili</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Hai" sort="Zhu, Hai" uniqKey="Zhu H" first="Hai" last="Zhu">Hai Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Mak, Nga Sze Amanda" sort="Mak, Nga Sze Amanda" uniqKey="Mak N" first="Nga Sze Amanda" last="Mak">Nga Sze Amanda Mak</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Yan, Yongqi" sort="Yan, Yongqi" uniqKey="Yan Y" first="Yongqi" last="Yan">Yongqi Yan</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yi" sort="Zhu, Yi" uniqKey="Zhu Y" first="Yi" last="Zhu">Yi Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32227493</idno><idno type="pmid">32227493</idno><idno type="doi">10.1002/jmv.25798</idno><idno type="wicri:Area/PubMed/Corpus">000112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000112</idno><idno type="wicri:Area/PubMed/Curation">000112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000112</idno><idno type="wicri:Area/PubMed/Checkpoint">000127</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000127</idno><idno type="wicri:Area/Ncbi/Merge">002677</idno><idno type="wicri:Area/Ncbi/Curation">002677</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.</title><author><name sortKey="Khalili, Jahan S" sort="Khalili, Jahan S" uniqKey="Khalili J" first="Jahan S" last="Khalili">Jahan S. Khalili</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Hai" sort="Zhu, Hai" uniqKey="Zhu H" first="Hai" last="Zhu">Hai Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Mak, Nga Sze Amanda" sort="Mak, Nga Sze Amanda" uniqKey="Mak N" first="Nga Sze Amanda" last="Mak">Nga Sze Amanda Mak</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Yan, Yongqi" sort="Yan, Yongqi" uniqKey="Yan Y" first="Yongqi" last="Yan">Yongqi Yan</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yi" sort="Zhu, Yi" uniqKey="Zhu Y" first="Yi" last="Zhu">Yi Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:32227493
|texte= Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:32227493" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |